Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2023 and 2024.
-
Tight liquidity NBB
Cash and receivables cover 2 % of short-term debt in 2024; threshold 65 %.
-
Busy address KBO
111 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2024
PREMIUM PHARMA RETAIL from Sint-Jans-Molenbeek, company number BE0833748256, closed financial year 2024 with a result of € -24,385 after tax. For that financial year PREMIUM PHARMA RETAIL recorded a gross margin of € -12,156 and equity of € -154,972. Compared with financial year 2023, the result moved from € -29,502 to € -24,385. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on October 31, 2025.
€ -154,972
▼ € 24,385 vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -24,385
▲ 17 % less loss than in 2023
Profit after tax over the fiscal year.
€ 1,849
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -173,572.
People and assets in 2024
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2024
€ 32,702
▲ 8% vs 2023
Loans from banks and other lenders, long and short.
€ 28,845
▲ 10% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 2,911
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Gross margin | € -21,865 | € -14,682 | € -19,391 | € -12,156 | ▲ € 7,235 |
| Profit after taxes | € -29,622 | € -22,888 | € -29,502 | € -24,385 | ▲ € 5,117 |
| Equity | € -78,197 | € -101,085 | € -130,587 | € -154,972 | ▼ € 24,385 |
| Total debts | € 130,525 | € 148,028 | € 173,406 | € 191,971 | ▲ 11% |
| Cash | € 681 | - | - | € 1,849 | |
| Retained profit | € -96,797 | € -119,685 | € -149,187 | € -173,572 | ▼ € 24,385 |
| Bank debt | € 0 | € 19,015 | € 30,392 | € 32,702 | ▲ 8% |
| Balance sheet total | € 52,328 | € 46,942 | € 42,819 | € 36,999 | ▼ 14% |
Key figures of PREMIUM PHARMA RETAIL, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to PREMIUM PHARMA RETAIL?
What happened at PREMIUM PHARMA RETAIL in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: loss of € 24,385. filed late Source: NBB ↗
- New establishment in Zaventem. KBO
- Olivier Lebbink became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 29,622 loss in 2021 to € 24,385 loss in 2024.
A new publication or filing at PREMIUM PHARMA RETAIL? We notify you, reason included.
Follow PREMIUM PHARMA RETAILDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind PREMIUM PHARMA RETAIL is Olivier Lebbink. Olivier Lebbink is also behind PREMIUM CONSULTING & MANAGEMENT and PREMIUM PHARMA.
Directors
According to the 2024 annual accounts
since 2017
Establishments
Establishment units
Physical locations of this company
Kolomstraat 1A
1080 Sint-Jans-Molenbeek
Excelsiorlaan 61
1930 Zaventem
Active since 1 September 2019
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 111 companies are registered at this address.
All companies at this address →MGL BATIMENT
€ 30,486 gross margin · 2024
CITY PROMOTION
€ -2,200 gross margin · 2025
GREENHILL
€ -7,520 gross margin · 2024
BOIS SAINT JEAN
€ 262,435 gross margin · 2025
ZOLFGAR
€ 86,334 revenue · 2025
+106 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0833.748.256
- VAT number
- BE 0833.748.256
- Registered office
- Kolomstraat 1A, 1080 Sint-Jans-Molenbeek
- Names & denominations
- PREMIUM PHARMA RETAIL · P.P.R OU PPR
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 15 February 2011
- Peppol
- Active · Active since 17 Jul 2024
- Activities · NACE
Vervaardiging van farmaceutische grondstoffen
Groothandel in farmaceutische en medische artikelen
Vervaardiging van geneesmiddelen